

Scientific Programme

Brest - June 10-13, 2009

Wednesday, June 10		
18:30-21:30	Opening Ceremony ECFS Award Welcome reception	Theater
Thursday, June 11		
07:15-08:15	Round tables	Salons C/D
	Modifier Genes – news and problems	A. Clément (FR)
	Mutation specific therapies – what's new?	B. Kerem (IL)
	Newborn Screening: equivocal cases	K. Southern (UK)
	Optimizing infection control in the hospital	G. Taccetti (IT)
	Treatment of atypical mycobacteria	D. Bilton (UK)
	CFTR in alveolar cells	C. Planes (FR)
	Correctors and Potentiators	L. Galletta (IT)
	Management of Haemoptysis	H. Heijerman (NL)
	Sinus and upper airways	R. Chiron (FR)
	Probiotics in Cystic Fibrosis	M. Cipolli (IT)
	Nutritional assessment in CF	A. Munck (FR)
	Intestinal Complications in CF	F. Huet (FR)
	Transition from child to adult CF services	A. Cunha (UK)
	Management of CFRD - role of CF Nurse or Diabetes Nurse?	S. Ockhorst (NL)
	Nebulizers, cleaning	L. Lannefors (SE)
	High Frequency Chest Wall Oscillation	M. McIlwaine (CA)
	Benchmarking and quality improvement	M. Stern (DE)
	PortCF Experience in UK	E. Gunn (UK)
	Chest CT protocols and monitoring	J. Davies (UK)
	Clinical trial design: do's and don'ts	H. Tiddens (NL)
Thursday, June 11		
08.30-10.00	Plenary I – CFTR: 20th Anniversary Celebration	Theater
	Moderators: S. Elborn (UK) / C. Férec (FR)	
08:30-09:00	Lap Chee Tsui (HK)	
09:00-09:30	J. Riordan (US)	
09:30-10:00	B. Kerem (IL)	
10:00-10:30	Coffee	Exhibition Hall
Thursday, June 11		
	Symposium 1 – Immunology/Pulmonology	Theater
10:30-12:00	Grand Rounds in Pulmonary Disease Moderators/ Expert panel: S. Bell (AU) - B. Fauroux (FR) - H. Heijerman (NL) - D. Bilton (UK) - G. Taccetti (IT)	
10:30-10:45	Abstract 277: Lung transplantation in patients with cystic fibrosis and <i>mycobacterium abscessus</i> infection – M. Gilljam (SE)	
10:45-11:00	Abstract 275: Infection by <i>Nocardia farcinica</i> in CF – M. Roussey (FR)	
11:00-11:15	Abstract 276: First colonisation with <i>P. aeruginosa</i> – only detected in the upper airways – eradicated with sinonasal	

Version (updated 3/10/2009)

	inhalation of Tobramycin – J. Mainz (DE)	
11:15-11:30	A pain in the neck – J. Greenwood (UK)	
11:30-11:45	Bilateral hilar lymphadenopathy in cystic fibrosis (CF) – when is it significant? – F. Perrin (UK)	
11:45-12:00	Aspergillus paraspinal abscess after lung transplantation in a teenage CF patient – P. Seddon (UK)	
	Best Case Presentation Award by the Expert Panel	
Thursday, June 11		
	Symposium 2 – Microbiology/Antibiotics	Multiplexe 3
10:30-12:00	Title: Designing the Optimum CF Microbiology Service Moderators: R. Cantón (SP) / M. Denton (UK)	
10:30-10:52	What is expected from the clinical viewpoint? – D. Peckham (UK)	
10:52-11:14	Detection and identification of CF pathogens – P. Plésiat (FR)	
11:14-11:36	Susceptibility testing : when, how and how frequently?– S. Aaron (CA)	
11:36-12:00	Genotyping and epidemiology – E. Mahenthalingam (UK)	
Thursday, June 11		
	Symposium 3 - Nutrition	Multiplexe 2
10:30-12:00	Title: Nutritional Challenges across the Lifespan Moderators: F. Hollander (NL) / A. Morton (UK)	
10:30-10:52	Nutritional Management of Infants – A. Munck (FR)	
10:52-11:14	Body Image, Disordered Eating and Psychosocial Aspects of Eating – A. Quittner (US)	
11:14-11:36	Nutritional Challenges in Pregnancy – A. Morton (UK)	
11:36-12:00	Nutrition in the Pre and Post-Transplant Patient – D. Kalnins (CA)	
Thursday, June 11		
	Symposium 4 – Genetics/Screening	
10:30-12:00	Title: Mutation Specific Therapies 2009 Moderators: G. Bellon (FR) / J. Riordan (US)	Amphitheatre
10:30-10:52	Mutation specific therapies PTC 124 – E. Kerem (IL)	
10:52-11:14	Mutation therapy Miglustat - F. Becq (FR)	
11:14-11:36	Challenges and Opportunities for Development of CFTR Modulators - C. Ordonez (US)	
11:36-12:00	Natural drugs for splicing - B. Kerem (IL)	
Thursday, June 11		
	Symposium 5 – Psychosocial / Nursing	
10:30-12:00	Title: Cystic Fibrosis in the family Moderators: A. Gravelle (CA) / J. de Vries (NL)	Multiplexe 1
10:30-10:52	Involving young children in their care – V. David (FR)	
10:52-11:14	Coping with the transition from childhood to adulthood - M. Bryon (UK)	
11:14-11:36	Well siblings – T. Havermans (BE)	
11:36-12:00	Parents and Partners: Challenges for the future – M. van Hattem (NL)	
12:00-14:30	Lunch	
13:30-14:30	Guided Poster Tours in the following categories: GI/Nutrition/Metabolic complications Microbiology Psychosocial Issues/ Nursing	
13:30-14:30	Poster Presenters in the following categories available at their	

Version (updated 3/10/2009)

	posters for discussion: Pulmonology/Immunology/Inflammation/New Therapies	
Thursday, June 11		
14:30-16:00	Workshop 1 – Psychosocial / Nursing	
	Title: Educational Issues	Multiplexe 1
	Moderators: J. de Vries (NL) / L. Goldbeck (DE)	
14:30-14:48	Abstract 386: Providing inpatient education on a segregated ward – J. Steel (UK)	
14:48-15:06	Abstract 396: Pedagogic drivers in therapeutic education for patients with Cystic Fibrosis – C. Berville (FR)	
15:06-15:24	Abstract 388: Experience of parents of CF pre-teenagers participating in a therapeutic education programme - P. Varlet (FR)	
15:24-15:42	Abstract 395: European survey on schooling of children, teenagers and young adults with cystic fibrosis – I. Sermet (EUR)	
15:42-16:00	Abstract 410: How we managed to improve a professional attitude in the nursing team to deal with topics of sexuality, fertility and reproduction in relation to CF patients – M. van Hattem (NL)	
Thursday, June 11		
14:30-16:00	Workshop 2 – Basic Science	
	Title: CFTR and Cell Biology	Meeting Room 2
	Moderators: M. Amaral (PT) / A. Edelman (FR)	
14:30-14:45	Overview – M. Amaral (PT)	
14:45-15:00	Abstract 71: COMMD1 promotes CFTR trafficking through inhibition of ubiquitination – L. Drévillon (FR)	
15:00-15:15	Abstract 70: Correction of the F508del-CFTR function by the Gonadotropin-Releasing hormone (GnRH) in polarized and non-polarized epithelial cells – N. Benz (FR)	
15:15-15:30	Abstract 92: Mitochondrial glutathione and decreased complex I activity in cystic fibrosis models – M. Kelly (FR)	
15:30-15:45	Abstract 68: Rescue of A455E CFTR by temperature, small molecule correctors and transcomplementation – L. Cebotaru (US)	
15:45-16:00	Abstract 115: New targeting method for nucleic acid transfer into the lung – F. Beilvert (FR)	
Thursday, June 11		
14:30-16:00	Workshop 3 – GI/Liver/Endo	
	Title: Gastrointestinal and Nutritional Issues	Amphitheatre
	Moderators: F. Huet (FR) / TBD	
14:30-14:45	Abstract 330: Proof of principle. Treatment of cystic fibrosis-related diabetes: a possible role for complementary metformin? – J. van den Berg (NL)	
14:45-15:00	Abstract 318: Fundoplication for cough in CF reduces exacerbations – A. Morice (UK)	
15:00-15:15	Abstract 344: Danish habits of cream and full cheeses – J. Sundstrup (DK)	
15:15-15:30	Abstract 315: Gallbladder dysfunction contributes to impaired bile salt homeostasis in cystic fibrosis – D. Debray (FR)	
15:30-15:45	Abstract 316: Detection of bile acids in sputum as a screening method for assessment of aspiration of duodenogastric contents in patients with cystic fibrosis – A. Pauwels (BE)	
15:45-16:00	Abstract 319: Immuno-Reactive Trypsine and extern pancreatic status in cystic fibrosis children – E. Chaillou (FR)	

Thursday, June 11		
14:30-16:00	Workshop 4 - Pulmonology	
	Title: Pathogenesis and Modulation of Lung Inflammation	Multiplexe 2
	Moderators: T. Wagner (DE) / R. Bals (DE)	
14:30-14:45	Abstract 218: Azithromycin is not able to decrease inflammatory process in cystic fibrosis human bronchial epithelial cells – V. Saint-Criq (FR)	
14:45-15:00	Abstract 219: Weak anti-inflammatory effects of glucocorticoids on CF bronchial epithelial cells – C. Rebeyrol (FR)	
15:00-15:15	Abstract 209: Comparison of Inflammatory responses to <i>Pseudomonas aeruginosa</i> Lipopolysaccharide isolates compared to <i>Staphylococcus aureus</i> Peptidoglycan – P. Buchanan (UK)	
15:15-15:30	Abstract 220: IP-10 induction after LPS stimulation is compromised in cystic fibrosis bronchial epithelial cells – M. Henke (DE)	
15:30-15:45	Abstract 203: Anoxia prolongs the life and functionality of polymorphonuclear leukocytes – P.Ø. Jensen (DK)	
15:45-16:00	Abstract 221: Drug specific T cells in patients with a history of non-immediate hypersensitivity reactions – P. Whitaker (UK)	
Thursday, June 11		
14:30-16:00	Workshop 5 – Clinical Trials/New Therapies	
	Title: The New Therapies' Pipeline	Theater
	Moderators: M. Mall (DE) / E. Alton (UK)	
14:30-14:45	Abstract 67: Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 – F. Van Goor (US)	
14:45-15:00	Abstract 97: Final results of a 14- and 28-day study of VX-770 in subjects with CF – F. Accurso (US)	
15:00-15:15	Abstract 98: Pharmacological characterization of a novel water-soluble activator of F508del-CFTR – J. Bertrand (FR)	
15:15-15:30	Abstract 102: The novel long acting ENaC blocker P643 has therapeutic effects in chronic cystic fibrosis-like lung disease in mice – Z. Zhou (DE)	
15:30-15:45	Abstract 116: Variations on hydrophobic domains in Lipophosphoramidates results in lung transfection's improvement and lower toxicity – T. Montier (FR)	
15:45-16:00	Abstract 117: Histidinylated linear PEIs as new DNA carriers for <i>in vitro</i> and <i>in vivo</i> gene transfer with low toxicity – P. Guégan (FR)	
Thursday, June 11		
14:30-16:00	Oral Poster Session I	
	Infection and Inflammation	Multiplexe 3
	Moderators: M. Denton (UK) / M. Fayon (FR)	
14:30-14:40	Abstract 130: Change in composition and structure of bacteria in the CF airway over one year – F.A. Stressmann (UK)	
14:40-14:50	Abstract 149: Monitoring of the Initial <i>Pseudomonas aeruginosa</i> Colonization in Cystic Fibrosis Patients Demonstrated High Clonal Diversity – R. Canton (SP)	
14:50-15:00	Abstract 156: Genotype based evaluation of eradication treatment of new <i>P. aeruginosa</i> infections in CF patients – F. De Baets (BE)	
15:00-15:10	Abstract 255: Dynamics of upper and lower airway colonisation with <i>P. aeruginosa</i> and <i>S. aureus</i> in CF-patients within 3.5 years – J. Mainz (DE)	
15:10-15:20	Abstract 252: Cytokine pattern in broncho-alveolar lavage in children with Cystic Fibrosis and infection with <i>Pseudomonas aeruginosa</i> – T. Frischer (AT)	
15:20-15:30	Abstract 152: Genotyping of <i>Pseudomonas aeruginosa</i> isolates from aquatic environment at a Swedish hospital and relation to infection of lung transplanted patients with <i>Pseudomonas</i> – E.	

Version (updated 3/10/2009)

	Johansson (SE)	
15:30-15:40	Abstract 89: Long acting β 2-agonist and corticosteroid restore airway glandular cell functionality altered by <i>Staphylococcus aureus</i> virulence factors – J.M. Zahm (FR)	
15:40-15:50	Abstract 169: Community-Acquired MRSA causes earlier infection than Hospital-Acquired MRSA in patients with cystic fibrosis – S. Campana (IT)	
15:50-16:00	Abstract 139: In vitro activity of tigecycline and other antibiotics against <i>Burkholderia cepacia</i> complex (Bcc) and other cystic fibrosis (CF)-associated Gram negative bacteria – M. Denton (UK)	
16:00-16:30	Coffee	Exhibition Hall
Thursday, June 11		
16:30-18:00	Workshop 6 – Genetics/Screening	
	Title: Genetics: Science and Practice	Multiplexe 3
	Moderators: C. Castellani (IT) / G. Cutting (US)	
16:30-16:52	Molecular tools for the diagnosis of CF and CFTR related disorders: what clinicians should know – M. Goossens (FR)	
16:52-17:07	Abstract 14: Comprehensive analysis of the French NBS cohort: Excellent mutation detection rate despite high allelic heterogeneity – M. des Georges (FR)	
17:07-17:22	Abstract 3: ETR-3 is a major regulator of CFTR pre-mRNA splicing – G. Dujardin (FR)	
17:22-17:37	Abstract 15: <i>In vivo</i> and <i>in vitro</i> effect of E831X mutation – A. Hinzpeter (FR)	
17:37-18:00	CFTR2 2009 Genotype/phenotype correlations for the clinician – G. Cutting (US)	
Thursday, June 11		
16:30-18:00	Workshop 7 – Micro / Antibiotics	
	Title: Bacterial Pathogen Identification and Susceptibility Testing: Lessons to be Learned	Multiplexe 2
	Moderators: B. Tümmler (DE) / C. Segonds (FR)	
16:30-16:45	Introduction: Changing challenges of the microbiology of the CF lung – D. Worlitzsch (DE)	
16:45-17:00	Abstract 132: EuroCareCF European Microbiology Quality Assurance Trials – B. Tümmler (DE)	
17:00-17:15	Abstract 142: Low rates of <i>Pseudomonas aeruginosa</i> (Pa) misidentification in Australian cystic fibrosis (CF) patients – S. Bell (AUS)	
17:15-17:30	Abstract 163: Colistin sulfate/tobramycin combination is superior for killing biofilm <i>P. aeruginosa</i> than monotherapy in vitro – G. Herrmann (DE)	
17:30-17:45	Abstract 164: Resistance in cystic fibrosis <i>Pseudomonas aeruginosa</i> strains is not mediated by common acquired antibiotic resistance genes – D. De Vos (BE)	
17:45-18:00	Abstract 181: Impact of strict anaerobes on the pathogenesis of lung infection in patients with cystic Fibrosis – M. Ulrich (DE)	
Thursday, June 11		
16:30-18:00	Workshop 8 - Physiotherapy	
	Title: Inhalation and Adjuncts to Physiotherapy	Multiplexe 1
	Moderators: L. Lannefors (SE) / C. Lejosne (FR)	
16:30-16:45	Introduction: L. Lannefors (SE)	
16:45-17:00	Abstract 298: A randomised, cross-over trial of upright sitting versus alternate side lying during nebulised delivery of medication in cystic fibrosis – R. Dentice (AU)	
17:00-17:15	Abstract 266: Effect of Positive Expiratory Pressure combined with Nebulization on Inhaled Dose : an <i>in vitro</i> Evaluation – G-	

Version (updated 3/10/2009)

	Reychler (BE)	
17:15-17:30	Abstract 264: Lung delivery of a new tobramycin nebuliser solution (150mg/1.5 ml) by an investigational eFlow® nebuliser is equivalent to TOBI® but in a fraction of time – O. Denk (DE)	
17:30-17:45	Abstract 265: Preclinical study of a new antibiotic for nebulisation – L. Vecellio (FR)	
17:45-18:00	Abstract 297: The use of NIV within a regional adult Cystic Fibrosis Centre – J. Barrett (UK)	
Thursday, June 11		
16:30-18:00	Workshop 9	
	Title: Epithelial Injury and Repair	Meeting Room 2
	Moderators: S. Randell (US) / M. Chanson (CH)	
16:30-17:00	Stem cell injury and repair – S. Randell (US)	
17:00-17:15	Abstract 90: Are basal cells progenitors of the human bronchiolar epithelium? – T. Jolly (FR)	
17:15-17:30	Abstract 91: Epithelial factors produced during the remodelling of the human airway epithelium – J. Roux (FR)	
17:30-17:45	Abstract 75: Connexin 26 is implied in the regulation of airway epithelium repair – S. Crespín (CH)	
17:45-18:00	Abstract 222: Cytokine production in the differentiating human airway epithelium – M. Chanson (CH)	
Thursday, June 11		
16:30-18:00	Workshop 10 – Nursing / Psychosocial	
	Title: Motivation and Attitude to Treatment	Amphitheatre
	Moderators: T. Havermans (BE) / M. Braithwaite (AU)	
16:30-16:48	Abstract 374: Improving self efficacy in adolescents and young adults with cystic fibrosis (CF) – C. Wainwright (AU)	
16:48-17:06	Abstract 367: Attitudes to Diabetes complicating Cystic Fibrosis using the Prochaska stage of change model – M. Wildman (UK)	
17:06-17:24	Abstract 368: Self-care: a qualitative study of adults with CF – D. Greenop (UK)	
17:24-17:42	Abstract 371: Exploration of personality, psychosocial factors and illness effect on adherence behaviour in CF – M. Braithwaite (AU)	
17:42-18:00	Abstract 398: Quality of Care and Quality of Life: Patient/Healthcare Perspectives – S. Armoni (IL)	
Thursday, June 11		
16:30-18:00	Oral Poster Session II	
	Clinical Care	Theatre
	Moderators: M. Ballmann (DE) / C. Haworth (UK)	
16:30-16:40	Abstract 146: Paranasal sinuses are a focus for <i>P. aeruginosa</i> (PA) lung infection in CF – H. Johansen (DK)	
16:40-16:50	Abstract 100: Effects of denufosal on sinusitis-related complaints in a phase 3 trial in cystic fibrosis patients – A. Mospan (US)	
16:50-17:00	Abstract 242: Respiratory exacerbations in children aged 0-3 years in the Australasian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) Study – C. Byrnes (AU)	
17:00-17:10	Abstract 243: Pre-flight evaluation of adult patients with cystic fibrosis – B. Skrede (NO)	
17:10-17:20	Abstract 88: Airway epithelial responses to hypertonic solutions: different <i>in vivo</i> responses in CF and non-CF human subjects – P. Middleton (AU)	
17:20-17:30	Abstract 448: Prevalence of renal impairment in children with cystic fibrosis (CF) – M. Fayon (FR)	
17:30-17:40	Abstract 333: Characteristics of visual function in adults with cystic fibrosis – K. Evans (UK)	
17:40-17:50	Abstract 346: The experience of using megestrol acetate (MA)	

Version (updated 3/10/2009)

	in a large UK adult CF centre – J. Barrett (UK)	
17:50-18:00	Abstract 310: Outcome in Cystic Fibrosis Liver Disease – M. Rowland (IE)	
Friday, June 12		
07:15-08:15	Round tables	Salons C/D
	Genetic counseling: difficulties in newborn screening	E. Bieth (FR)
	Technology for genetic testing	H. Cuppens (BE)
	Bacterial genomics	E. Mahenthiralingam (UK)
	MRSA: do we have to be ready for new emerging clones?	R. Cantón (SP)
	Universal typing of bacteria?	P. Drevinek (CZ)
	CF Pig	E. Wolf (DE)
	CFTR folding	I. Callebaut (FR)
	Anti-inflammatory treatment	M. Fayon (FR)
	Travel with CF	S. Bell (AU)
	Nutrition and Disordered Eating	M. Bryon (UK)
	Cystic Fibrosis Related Diabetes	M. Ballmann (DE)
	Pain Management Measures	T. Besier (DE)
	When is the best time to discuss fertility?	A. Tsang (CA)
	Therapeutic education	V. David (FR)
	Exercise Prescription	H. Hebestreit (DE)
	Physiotherapy - when to start in screened infants?	H. Gauchez (FR)
	Data control in Registries	P. Wenzlaff (DE)
	Nasal PD: interpretation of tracings	M. Wilschanski (IL)
	Lung clearance index for beginners	A. Linblad (SE)
Friday, June 12		
08:30-10:00	Symposium 6 – New Therapies	
	Title: Clinical Trials	Theatre
	Moderators: K. De Boeck (BE) / A. Reimann (DE)	
08:30-08:52	A UK CF Gene Therapy Consortium – E. Alton (UK)	
08:52-09:14	New drugs: add on or replace? (Burden of therapy, design, regulatory) – C. Goss (US)	
09:14-09:36	Clinical research: bringing drugs and patients together – S. Elborn (UK)	
09:36-10:00	ECFS Clinical Trials Network – K. De Boeck (BE)	
Friday, June 12		
08:30-10:00	Symposium 7- Genetics	
	Title: Advances in genetics and screening	Amphitheatre
	Moderators: C. Férec (FR) / M. Stuhmann (DE)	
08:30-08:52	Carrier screening: ECFS recommendations – M. Macek (CZ)	
08:52-09:14	Newborn screening, benefits, methods of screening - C. Castellani (IT)	
09:14-09:36	CFTR related disorders – C. Férec (FR)	
09:36-10:00	North American modifiers gene study - J. Zielenski (CA) / S. Blackman (US)	
Friday, June 12		
08:30-10:00	Symposium 8 - Pulmonology	
	Title: Pro/Con	Multiplexe 1
	Moderators: J. Davies (UK) / S. Bell (AU)	
	CF lung disease: inflammation comes first	
08:30-08:47	Pro: M. Fayon (FR)	

Version (updated 3/10/2009)

08:47-09:04	Con: C. Wainwright (AU)	
09:04-09:15	Discussion	
	Patients with pan resistant micro-organisms should not be transplanted	
09:15-09:32	Pro: P. Noone (US)	
09:32-09:49	Con: R. Souilamas (FR)	
09:49-10:00	Discussion	
Friday, June 12		
	Symposium 9 - Physiotherapy	
08:30-10:00	Title: Physiotherapy Management at the ends of the spectrum in CF	Multiplexe 3
	Moderators: M. McIlwaine (CA) / H. Gauchez (FR)	
08:30-08:52	Management of well infants diagnosed with newborn screening - A. Prasad (UK)	
08:52-09:14	Management of children with respiratory symptoms - M. McIlwaine (CA)	
09:14-09:36	Management of the adult with normal lung function - J. Bradley (UK)	
09:36-10:00	Management of the adult in acute respiratory failure - B. Button (AU)	
Friday, June 12		
	Symposium 10 - GI/Liver/Endo	
08:30-10:00	Title : Bone health in CF	Multiplexe 2
	Moderators: C. Haworth (UK) / I. Sermet-Gaudelus (FR)	
08:30-08:52	Body composition and assessment of bone health - M.L. Bianchi (IT)	
08:52-09:14	Aetiology of bone disease - I. Sermet-Gaudelus (FR)	
09:14-09:36	Nutritional aspects of bone disease - S. Wolfe (UK)	
09:36-10:00	Reduced bone mineral density: which therapeutic options? - C. Haworth (UK)	
10:00-10:30	Coffee	Exhibition Hall
Friday June 12		
	Symposium 11 - Epidemiology/Registry	
10:30-12:00	Title: Improving data quality of the European registry	Multiplexe 2
	Moderators: S. Ravilly (FR) / H. Olesen (DK)	
10:30-10:52	Z-score and nutrition - B. Wiedermann (DE)	
10:52-11:14	Survival analysis - V. Scotet (FR)	
11:14-11:36	FEV1 percentile - K. De Boeck (BE)	
11:36-12:00	Most recent Update - H. Olesen (DK)	
Friday, June 12		
	Symposium 12 - Basic science	
10:30-12:00	Title: Tools for translational CFTR research	Meeting Room 2
	Moderators: B. Scholte (NL) / C. Coraux (FR)	
10:30-10:52	New animal models - D. Stoltz (US)	
10:52-11:14	Lessons from mice - H. de Jonge (NL)	
11:14-11:36	ENaC Over-expressing mice - M. Mall (DE)	
11:36-12:00	In Vitro use of primary cells - C. Coraux (FR)	

Friday, June 12		
	Symposium 13 - Pulmonology	
10:30-12:00	Title: Monitoring lung disease	Theater
	Moderators: H. Hebestreit (DE) / B. Fauroux (FR)	
10:30-10:52	Monitoring lung disease in young non sputum producing children - C. Van der Ent (NL)	
10:52-11:14	Lung function and exercise tolerance - H. Hebestreit (DE)	
11:14-11:36	BAL and breath condensate - F. Ratjen (CA)	
11:36-12:00	NIV: When to start and when to stop? - B. Fauroux (FR)	
Friday, June 12		
	Symposium 14 - Microbiology/Antibiotics	
10:30-12:00	Title: Prevention and treatment of lung infections	Multiplexe 3
	Moderators: P. Drevinek (CZ) / G. Chabanon (FR)	
10:30-10:52	Can we prevent acquisition of CF pathogens from the environment? - C. Moser (DK)	
10:52-11:14	Should we treat anaerobes and microaerophiles? - D. Worlitzsch (DE)	
11:14-11:36	Antibiotic prophylaxis in CF: What do we do now? - A. Smyth (UK)	
11:36-12:00	First infection with P. aeruginosa: Diagnosis, monitoring and therapy - T. Pressler (DK)	
Friday, June 12		
	Symposium 15 - Nursing	
10:30-12:00	Title: Life after transplant	Amphitheatre
	Moderators: S. Madge (UK) / C. Cracowski (FR)	
10:30-10:52	Is there an opportunity to say "No"? - K. Dack (UK)	
10:52-11:14	Quality of Life before and after transplant - T. Lunnon-Wood (UK)	
11:14-11:36	Pregnancy after transplant - A. Tsang (CA)	
11:36-12:00	End stage management following transplant - F. Finlayson (AU)	
Friday, June 12		
10:30-12:00	Oral Poster Session III:	
	Genetics and CFTR	Multiplexe 1
	Moderators: H. Cuppens (BE) / M. Macek (CZ)	CF suggests P. Fanen
10:30-10:40	Abstract 1: New putative cis-acting regulatory variations in the CFTR gene - V. Viart (FR)	
10:40-10:50	Abstract 7: The French CF Laboratory Network: seven years experience - E. Girodon (FR)	
10:50-11:00	Abstract 55: Identification of CFTR rearrangements by a CGH locus specific array - S. Quémener (FR)	
11:00-11:10	Abstract 80: Proteomic analysis of G551D and R117H-CFTR associated proteins - L. Teng (FR)	
11:10-11:20	Abstract 22: Clinical phenotype for the G551D mutation - D. Comer (UK)	
11:20-11:30	Abstract 86: Functional Evaluation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) in human monocytes - P. Melotti (IT)	
11:30-11:40	Abstract 77: CFTR and Tight Junctions in Cultured Bronchial Epithelial Cells - H. Nilsson (SE)	
11:40-11:50	Abstract 8: Complete sequencing of the CFTR gene using new generation GS-FLX sequencing technology - H. Cuppens (BE)	
11:50-12:00	Abstract 99: Roscovitine : a novel corrector for the functional rescue of F508del-CFTR protein - C. Norez (FR)	

Version (updated 3/10/2009)

12:00-14:30	Lunch	
13:30-14:30	Guided Poster Tours in the following categories: Screening/Diagnosis/Genetics CFTR-Cell Biology/Physiology Physiotherapy	
13:30-14:30	Poster Presenters in the following categories available at their posters for discussion: Registry /Epidemiology/ Other Issues	
Friday, June 12		
Workshop 11 - Pulmonology		
14.30-16.00	Title: From recognizing early lung damage to optimization of transplantation in CF lung disease Moderators: S. Elborn (UK) / H. Heijerman (NL)	Theatre
14:30-14:45	Abstract 273: CT-detected early structural lung disease is progressive in infants and preschool children – L. Mott (AU)	
14:45-15:00	Abstract 272: Bronchiectasis (BE) on CT is a strong predictor of respiratory tract exacerbations in children with CF – M. Loeve (NL)	
15:00-15:15	Abstract 157: Interim outcomes of a <i>Pseudomonas aeruginosa</i> (Pa) eradication protocol in young children in the Australasian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) Study – J. Cheney (AU)	
15:15-15:30	Abstract 256: Synchronisation of intravenous (IV) antibiotic and <i>in vitro</i> susceptibility of sputum <i>Pseudomonas aeruginosa</i> (PA) does not influence outcome of care of adult CF patients - a prospective study – I. Sequeiros (UK)	
15:30-15:45	Abstract 250: Lactate as a non-invasive marker of CF lung inflammation – T. Bensele (DE)	
15:45-16:00	Abstract 271: Superiority of ATG induction therapy in lung transplant recipients with cystic fibrosis – P. Jaksch (AT)	
Friday, June 12		
Workshop 12 – GI/Liver/Endo		
14:30-16:00	GI Case Presentations Moderators/Expert Panel: J. Sarles (FR) / M. Stern (DE) / M. Cipolli (IT) / J. Walkowiak (PL) / A. Morton (UK)	Amphitheatre
14:30-14:41	Cutaneous manifestations as a rare initial presentation of cystic fibrosis – G. Hafen (CH)	
14:41-14:52	Renal Amyloidosis Complicating Cystic Fibrosis – L. Bober (UA)	
14:52-15:03	A rare cause of abdominal pain in an adolescent girl – D. Tjesic-D (HR)	
15:03-15:14	Gastrocutaneous Fistula After The Removal Of The Gastrostomy Tube – A. Palamarthy (UK)	
15:14-15:25	Hemodynamic significance of paraumbilical vein in portal hypertension in cystic fibrosis patient – I. Asherova (RU)	
15:25-15:36	Recurrent abdominal pain: a lesson for adult physicians – N. Simmonds (UK)	
15:36-15:47	Twin sisters with similar, severe, gastrointestinal symptoms – G. Goncalves (PT)	
15:47-15:58	Psoriatic arthritis and recurrent pancreatitis in a young boy with cystic fibrosis: a case report – E. Hatziaorou (GR)	
	Best Case Presentation Award by the Panel	
Friday, June 12		
Workshop 13 – Basic Science		
14.30-16.00	Title: Ion Transport, Inflammation and Pharmacology Moderators: O. Zegarra-Moran (IT) / P. Barbry (FR)	Meeting Room 2
14:30-14:45	Overview – O. Zegarra-Moran (IT)	
14:45-15:00	Abstract 87: The antimicrobial peptide LL-37 modulates the inflammatory and host defense response of human neutrophils –	

Version (updated 3/10/2009)

	R. Bals (DE)	
15:00-15:15	Abstract 74: Agonists of peroxisome proliferator activated receptor gamma (PPAR γ) modulate transepithelial anion secretion in human bronchial epithelial cells – M. Duszyck (US)	
15:15-15:30	Abstract 76: Connexin channels mediate PGE2-dependent regulation of CFTR activity in Calu-3 cells – D. Losa (CH)	
15:30-15:45	Abstract 216: Allergic inflammation produces a hypersecretory airway ion transport phenotype in mice – P. Anagnostopoulou (DE)	
15:45-16:00	Abstract 217: Accumulation of NKT cells in tissues of cystic fibrosis mice – N. Siegmann (DE)	
Friday, June 12		
	Workshop 14 – Registry/Epidemiology	
14:30-16:00	Title: Identification of Best Practices Moderators: C. Colombo (IT) / A. Mehta (UK)	Multiplexe 2
14:30-14:45	What patients want to know – experience from ECORN-CF – T. Wagner (DE)	
14:45-15:00	Abstract 416: Changes in Cystic Fibrosis mortality and persisting gender inequalities in Australia: 1979 – 2005 – D. Reid (AU)	
15:00-15:15	Abstract 424: UMD-CFTR: a database dedicated to CF and CFTR-related diseases – C. Bareil (FR)	
15:15-15:30	Abstract 415: International benchmarking for cystic fibrosis patient outcomes using registry data – G. Sims (AU)	
15:30-15:45	Abstract 419: Criteria for diagnosis of CF in the French Registry – L. Lemonnier (FR)	
15:45-16:00	Abstract 439: Implementation, uptake and impact of a cystic fibrosis electronic patient record system – D. Peckham (UK)	
Friday, June 12		
	Workshop 15 - Physiotherapy	
14.30-16.00	Title: New Trends in Physiotherapy Moderators: L. Smolikova (CZ) / B. Borel (FR)	Multiplexe 1
14:30-14:45	Introduction: L. Smolikova (CZ)	
14:45-15:00	Abstract 280: Validation of the MST-25: an extension of the modified shuttle test (MST) – M. Elkins (AU)	
15:00-15:15	Abstract 281: Mathematical modelling of oxygen uptake during recovery from exercise – D. Stevens (UK)	
15:15-15:30	Abstract 282: Desaturation on 3-minute step test is associated with impaired outcomes at 12 months in adults with cystic fibrosis – A. Holland (AU)	
15:30-15:45	Abstract 293: Better satisfaction of cystic fibrosis paediatric patients with autogenic drainage associated to exercise compared to conventional chest physiotherapy – P. Reix (FR)	
15:45-16:00	Abstract 289: Respiratory exacerbations and muscle strength in adult patients with cystic fibrosis – B. Vrijssen (BE)	
16:00-16:30	Coffee	
Friday, June 12		
	Workshop 16 – Basic Science	
16:30-18:00	Late Breaking Science Moderators: M. Gray (UK) / F. Dufour (FR)	Amphitheatre
	Overview of ECFS Basic Science conference 2009 – M. Gray (UK)	
	TMEM16A as a novel candidate for the Calcium-activated Chloride Channel (CaCC) in CF airways - possible implications for new therapeutic strategies – L. Galletta (IT)	
	Estrogen-mediated inhibition of CaCC - could this explain the gender gap in CF? – R. Coakley (US)	

Friday, June 12		
	Workshop 17 – Pulmonology/Immunology/Inflammation	
16:30-18:00	Title: Clinical Trials in CF Lung Disease	Theatre
	Moderators: H. Tiddens (NL) / D. Bilton (UK)	
16:30-16:45	Abstract 101: Relationship between pulmonary exacerbations and lung function decline in a six month trial of denufosol – F. Accurso (US)	
16:45-17:00	Abstract 105: Effective treatment of chronic <i>Pseudomonas aeruginosa</i> (Pa) infection with tobramycin inhalation powder in CF patients – M. Konstan (US)	
17:00-17:15	Abstract 107: Effect of multiple courses of Aztreonam Lysine for Inhalation (AZLI) on FEV1 and weight in patients with cystic fibrosis (CF) and <i>Pseudomonas aeruginosa</i> (PA): Analysis of 18 month data from CP-AI-006 – C. Oermann (US)	
17:15-17:30	Abstract 95: Randomised, double blind, placebo-controlled Phase III Study of Bronchitol (inhaled dry powder mannitol) in Cystic Fibrosis (CF) – D. Bilton (UK)	
17:30-17:45	Abstract 96: Safety/Efficacy of Inhaled Human Alpha-1 Antitrypsin (AAT) in CF: A Phase II Clinical Study – E. Kerem (IL)	
17:45-18:00	Abstract 114: Activity of liposomal formulations on sputum isolated from CF Patients – A. Omri (CA)	
Friday, June 12		
	Workshop 18 – Genetics and Screening	
16.30-18.00	Title: Implementation of Screening Strategies Worldwide	Multiplexe 2
	Moderators: A. Munck (FR) / A. Mehta (UK)	
	Introduction – P. Farrell (to include Abstract 30)	
	Abstract 31: Cystic fibrosis Heelprick among a newborn Population In the Netherlands: the CHOPIN-study - A Vernooij-van Langen (NL)	
	Abstract 38: Implementation of the UK Newborn Screening Programme – K. Southern (UK)	
	Abstract 52: Genetic aspect of two-year experience in cystic fibrosis newborn screening program in Poland – A. Norek (PL)	
	Abstract 32: Cystic Fibrosis (CF) Newborn Screening (NBS) - Comparison of an IRT-PAP with an IRT-DNA based protocol in a German population – O. Sommerburg (DE)	
	Abstract 420: Extensive carrier testing and CF birth prevalence: Evidence for a negative correlation – C. Castellani (IT)	
	Discussion time	
Friday, June 12		
	Workshop 19 – Microbiology/Antibiotics	
16:30-18:00	Title: New Insights into Prevention and Eradication of Infection	Multiplexe 3
	Moderators: S. Aaron (CA) / G. Chabanon (FR)	
16:30-16:45	Abstract 180: Detection of anaerobic bacteria in bronchoalveolar lavage fluid from paediatric CF patients – M. Tunney (UK)	
16:45-17:00	Abstract 148: Prevention of initial <i>P. aeruginosa</i> infection in children with cystic fibrosis: a multi-centre double-blind randomised controlled trial – G. Tramper-Stranders (NL)	
17:00-17:15	Abstract 151: An aerosol decay model of <i>Pseudomonas aeruginosa</i> survival – I. Clifton (UK)	
17:15-17:30	Abstract 184: Treatment of Non-Tuberculous Mycobacteria in Adults with Cystic Fibrosis – C. Haworth (UK)	
17:30-17:45	Abstract 170: Eradication of methicillin resistant <i>Staphylococcus aureus</i> in cystic fibrosis – M. Kappler (DE)	
17:45-18:00	Abstract 137: <i>Burkholderia cenocepacia</i> : nearing the end? – E. Spencer (UK)	
Friday, June 12		

Version (updated 3/10/2009)

	Workshop 20 – Nursing/Psychosocial	
16:30-18:00	Title: Complex case presentations	Multiplexe 1
	Expert panel: A. Gravelle (CA) / K. Colpaert (BE)/ M. Kirszenbaum (FR) / G. Ullrich (DE)	
	Case Presentations	
	Best case presentation award	
Saturday, June 13		
09:00-10:30	Symposium 16 – GI	
	Title: GI challenges in CF	Multiplexe 2
	Moderators: A. Munck (FR) / J. Walkowiak (PL)	
09:00-09:22	Pancreatitis, CF and genetics – P. Durie (CA)	
09:22-09:44	Enzyme therapy dose and efficacy – J. Sarles (FR)	
09:44-10:06	CFTR and intestinal function - M. Drumm (US)	
10:06-10:30	Does enteropathy in CF really exist? - M. Wilschanski (IL)	
Saturday June 13		
09:00-10:30	Symposium 17	
	Title: CF and innate immunity	Multiplexe 1
	Moderators: G. Döring (DE) / C. Moser (DK)	
09:00-09:22	CFTR and inflammation – A. Edelman (FR)	
09:22-09:44	Toll receptors and CF – M. Chignard (FR)	
09:44-10:06	Developing and Sustaining Airway Inflammation – S. Randell (US)	
10:06-10:30	Prospect for anti inflammatory therapy – M. Griese (DE)	
Saturday, June 13		
	Symposium 18 – Immunology/Pulmonology	
09:00-10:30	Title: Diagnosis and Management of rare and new pathogens	Meeting Room 2
	Moderators: H. Heijerman (NL) / P. Drevinek (CZ)	
09:00-09:22	Non Tuberculous Mycobacteria – H. Heijerman (NL)	
09:22-09:44	Aspergillus – M. Skov (DK)	
09:44-10:06	Burkholderia cepacia complex – J. Govan (UK)	
10:06-10:30	Less common Gram negative Microorganisms- N. Høiby (DK)	
Saturday, June 13		
	Symposium 19 – Basic Science	
09:00-10:30	Title: 20 years of CFTR	Theatre
	Moderators: P. Lehn (FR) / F. Becq (FR)	
09:00-09:22	CFTR processing – J. Riordan (US)	
09:22-09:44	CFTR folding – I. Callebaut (FR)	
09:44-10:06	CFTR structure and function – D.N. Sheppard (UK)	
10:06-10:30	CFTR bicarbonate – P. Quinton (US)	
Saturday, June 13		
	Symposium 20 – Psychosocial / Nursing	
09:00-10:30	Title: Fertility and Pregnancy	Amphitheatre
	Moderators: G. Thorpe-Beeston (UK) / S. Madge (UK)	
09:00-09:22	ECFS Consensus guidelines – S. Madge (UK)	

Version (updated 3/10/2009)

09:22-09:44	Pre-conception planning when, what, and how? – H. Oxley (UK)	
09:44-10:06	Fertility and assisted reproduction – impact on health – D. Hubert (FR)	
10:06-10:30	Managing parenthood with CF – K. Colpaert (BE)	
10:30-11:00	Coffee	Exhibition Hall
Saturday, June 13		
	Plenary II	
11:00-12:30	Title: Partnerships for new treatment	Theatre
	Moderators: C. Castellani (IT) / P. Lehn (FR)	
11:00-11:30	How treatment improves Quality of Life - A. Quittner (US)	
11:30-12:00	Clinical Trials: Priorities and challenges - H. Tiddens (NL)	
12:00-12:30	Patient organisations' contribution to clinical research - F. Dufour (FR)	
12.30-13.00	Closing Ceremony	Theatre